Heron Therapeuti (HRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $59.08M
Last updated: Nov 17, 2026 at 4:41 PM ET
Heron Therapeuti (HRTX) Stock Chart
Heron Therapeuti (HRTX) has a latest price of $0.28 on Nov 17, 2026, 82.1% below its 52-week high of $1.57. Its price fell 74.3% over the past 12 months. The month-end price fell 98.1% over the 10 years through Oct 2026, a compound annual decline of 32.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $38.85 in Jun 2018 and its lowest $0.28 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart HRTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for HRTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 10.4%, and over 6 months it fell 66.7%. The month-end price fell 56.4% over the 3 years through Oct 2026, a compound annual decline of 24.2%.
| Period | Change |
|---|---|
| 1 month | -21.8% |
| 3 months | -10.4% |
| 6 months | -66.7% |
| 12 months | -74.3% |
| 12 months, with dividends | -74.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -56.4% | -24.2% |
| 5 years | -97.5% | -52.1% |
| 10 years | -98.1% | -32.8% |
Price by Year
Its best calendar year was 2018, when the price rose 43.3%, and its weakest was 2022, when it fell 72.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.28 | -78.6% |
| 2025 | $1.30 | -15.0% |
| 2024 | $1.53 | -10.0% |
| 2023 | $1.70 | -32.0% |
| 2022 | $2.50 | -72.6% |
| 2021 | $9.13 | -56.9% |
| 2020 | $21.16 | -9.9% |
| 2019 | $23.50 | -9.4% |
| 2018 | $25.94 | +43.3% |
| 2017 | $18.10 | +38.2% |
Trading Range
The price is 13.2% below its 50-day average of $0.33 and 55.5% below its 200-day average of $0.63.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.28 | |
| 52-week high | $1.57 | -82.1% |
| 52-week low | $0.26 | +8.1% |
| 50-day average | $0.33 | -13.2% |
| 200-day average | $0.63 | -55.5% |
Price Risk
Over 3 years, its largest fall from a peak was 93.0%.
| Measure | Value |
|---|---|
| 1-year beta | 2.05 |
| Largest fall, 1 year | -81.9% |
| Largest fall, 3 years | -93.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About HRTX
What is HRTX's 1-year price change?
Heron Therapeuti's price fell 74.3% over the past 12 months. With dividends included, the 12-month total return was -74.3%.
What is HRTX's 5-year price change?
Heron Therapeuti's month-end price fell 97.5% over the 5 years through Oct 2026, a compound annual decline of 52.1%. These figures leave out dividends.
What is HRTX's 52-week high and low?
Heron Therapeuti's 52-week high is $1.57 and its 52-week low is $0.26. Its latest price of $0.28 on Nov 17, 2026 is 82.1% below the high.
What is HRTX's beta?
Heron Therapeuti's 1-year beta against the S&P 500 is 2.05, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 81.9%.
Is the HRTX chart free?
Yes. Advanced Charting for HRTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
HRTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors